Hong Kong's First 2022 Biotech IPO Debuts

Plus Other Broad Funding Across Modalities

 
• By Dexter Jie Yan
fund raising
VC/PE investors continued injecting capitals into Chinese biotechs, and small molecule developers obtained the largest share. • Source: Alamy

More from China

More from Focus On Asia